Herein, we present a case of an EGFR-mutant NSCLC patient with an acquired C797S mutation without T790M resistance to osimertinib who achieved prolonged disease control with gefitinib plus bevacizumab. This evidence concerns the gene EGFR and non-small cell lung carcinoma.